Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China NT Pharma Group CoHKSE:01011 -6.67%1 Dividend Payout Ratio is 0.00 as of Dec. 2025. GuruFocus rates HKSE:01011 with a GF Score™ of 1/100. The stock has 4 warning signs investors should review. Among 446 Drug Manufacturers companies, China NT Pharma Group Co ranks worse than 224215.02% on this metric.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. China NT Pharma Group Co's Dividend Payout Ratio for the
months ended in Dec. 2025 was 0.00.
The historical rank and industry rank for China NT Pharma Group Co's Dividend Payout Ratio or its related term are showing as below:
During the past 13 years, the highest Dividend Payout Ratio of China NT Pharma Group Co was 0.22. The lowest was 0.10. And the median was 0.16.
HKSE:01011's Dividend Payout Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.38 * Ranked among companies with meaningful Dividend Payout Ratio only.
During the past 13 years, the highest Trailing Annual Dividend Yield of China NT Pharma Group Co was 22.70%. The lowest was 0.00%. And the median was 1.51%.
China NT Pharma Group Co (HKSE:01011) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
China NT Pharma Group Co Dividend Payout Ratio Related Terms
China NT Pharma Group Co Dividend Payout Ratio Historical Data
* Premium members only.
The historical data trend for China NT Pharma Group Co's Dividend Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China NT Pharma Group Co Dividend Payout Ratio Chart
HKSE:01011 vs ZTS: Dividend Payout Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China NT Pharma Group Co's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China NT Pharma Group Co Dividend Payout Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China NT Pharma Group Co's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where China NT Pharma Group Co's Dividend Payout Ratio falls into.
China NT Pharma Group Co Dividend Payout Ratio Calculation
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
China NT Pharma Group Co's Dividend Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China NT Pharma Group Co (HKSE:01011) has a Dividend Payout Ratio of 0.00 as of Dec. 2025. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on China NT Pharma Group Co and its competitors. Over the past decade, China NT Pharma Group Co's Dividend Payout Ratio has ranged from 0.10 to 0.22. According to the industry distribution chart, China NT Pharma Group Co ranks #999999 out of 446 companies in the Drug Manufacturers industry.
Is China NT Pharma Group Co's Dividend Payout Ratio too high?
China NT Pharma Group Co's current Dividend Payout Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 0.22. Based on the distribution chart, China NT Pharma Group Co ranks #999999 out of 446 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, China NT Pharma Group Co has a GF Score™ of 1/100, reflecting its overall financial health beyond just this single metric.
How does China NT Pharma Group Co's Dividend Payout Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China NT Pharma Group Co ranks #999999 out of 446 companies for Dividend Payout Ratio. This places China NT Pharma Group Co in the lower half of its industry. The industry median Dividend Payout Ratio is 0.38. Historically, China NT Pharma Group Co's own Dividend Payout Ratio has ranged from 0.10 to 0.22 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Drug Manufacturers company?
The median Dividend Payout Ratio among Drug Manufacturers companies is 0.38, based on 446 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on China NT Pharma Group Co and its competitors. For the Drug Manufacturers industry, the median Dividend Payout Ratio is 0.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China NT Pharma Group Co's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China NT Pharma Group Co stock overvalued right now?
China NT Pharma Group Co (HKSE:01011) has a current Dividend Payout Ratio of 0.00. The current Dividend Payout Ratio is 0.00. China NT Pharma Group Co's overall GF Score™ is 1/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For China NT Pharma Group Co (HKSE:01011), the current Dividend Payout Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
China NT Pharma Group Co Ltd is a technology-based pharmaceutical company. It is engaged in research and development, production, and sale of private-label drugs, as well as the provision of pharmaceutical marketing and promotion services in China. It focused on the research, development, production, and sales of orthopedic, psychiatric, and oncology drugs. The Group's operations are regarded as having two operating and reportable segments, namely Agency Services and Healthcare Related Services. The company generates maximum of its revenue from Healthcare Related Services.
1GF Score
Get the complete analysis for HKSE:01011
Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01011 has been successfully added to your 
